Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells (Q38717289)
Jump to navigation
Jump to search
scientific article published on 5 February 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells |
scientific article published on 5 February 2017 |
Statements
1 reference
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells (English)
1 reference
Wei Wang
1 reference
Jin Zhou
1 reference
Lujie Zhao
1 reference
Shulin Chen
1 reference
5 February 2017
1 reference
1 reference
Identifiers
1 reference